• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.03% Nasdaq Up0.17%

    NPS Pharmaceuticals, Inc. (NPSP)

    -NasdaqGS
    35.06 1.18(3.48%) Dec 24, 1:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    NPS Pharmaceuticals, Inc.
    550 Hills Drive
    Bedminster, NJ 07921
    United States - Map
    Phone: 908-450-5300
    Fax: 908-450-5351
    Website: http://www.npsp.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:207

    Business Summary 

    NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The company also develops Natpara that is under Phase 3 clinical trial for the treatment of adult hypoparathyroidism; NPSP790 and NPSP795 calcilytic compounds, which are in Phase 1 clinical trial for application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria; and Teduglutide that is under preclinical stage for pediatric indications. It has collaborative agreements with GlaxoSmithKline to collaborate on the research, development, and commercialization of calcium receptor active compounds to treat osteoporosis and other bone metabolism disorders; and Kyowa Hakko Kirin Co. Ltd. to develop and commercialize compounds for the treatment of hyperparathyroidism. The company was founded in 1986 and is based in Bedminster, New Jersey.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on NPS Pharmaceuticals, Inc.

    Corporate Governance 
    NPS Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 1. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 1; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Francois Nader M.D., M.B.A., 57
    Chief Exec. Officer, Pres and Director
    1.33M7.66M
    Mr. Luke M. Beshar CPA, 55
    Chief Financial Officer and Exec. VP
    692.00K5.24M
    Ms. Susan E. Graf RPh, MBA, 41
    VP of Corp. Devel. & Strategy
    315.00K0.00
    Dr. Roger J. Garceau M.D., FAAP, 60
    Chief Medical Officer and Exec. VP
    680.00K2.24M
    Mr. Eric Pauwels , 52
    Sr. VP and Pres of NPS Pharma International
    686.00K0.00
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders